Evidence map›Paper›PMID 42728347›Full record

ArticleOncogene2026

Circular RNA MCM3 recruits USP49 to stabilize PTBP1 and promote cisplatin resistance in cervical squamous cell carcinoma.

Chenchen Zhu, Ying Wei, Yuebo Li, Zhengzheng Chen, Ying Zhou, Hanyuan Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chenchen ZhuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Ying WeiDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Yuebo LiDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Zhengzheng ChenDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Ying ZhouDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. caddiezy@ustc.edu.cn.ORCID http://orcid.org/0000-0001-8992-7897
Hanyuan LiuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. liuhanyuan123@ustc.edu.cn.ORCID http://orcid.org/0009-0005-6866-7949

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82172773, 82473382National Natural Science Foundation of China (National Science Foundation of China) 82503869
6 · The paper itself

Abstract

Circular RNA MCM3 is upregulated in platinum-resistant cervical squamous cell carcinoma (CSCC) and is associated with poor patient prognosis. However, its role in chemoresistance and the underlying mechanism remain undefined. Here, we demonstrate that circMCM3 drives cisplatin resistance both in vitro and in vivo by enhancing cell proliferation, inhibiting apoptosis and reducing DNA damage. Mechanistically, circMCM3 recruits the deubiquitinase USP49 to stabilize PTBP1, which binds to and stabilizes CCND1 mRNA, thereby facilitating cell cycle transition and reducing DNA damage. Notably, knockdown of PTBP1 or CCND1 abrogates circMCM3-mediated cisplatin resistance, supporting the existence of a functional circMCM3-USP49-PTBP1-CCND1 axis. Collectively, our findings identify circMCM3 as a critical regulator of platinum resistance and suggest that targeting this axis may represent a promising therapeutic strategy for patients with platinum-resistant CSCC.

Identifiers

PMID42728347

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.